All In Biotech

NDA 020238 · Medtech Products

Tagamet Hb

Cimetidine · Oral · Histamine-2 Receptor Antagonist

Last checked: Nov 21, 2026Latest source record: May 24, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Jun 19, 1995

Approved uses

3

Original approval plus efficacy supplements

Registered trials

42

8 Phase 3, 2 recruiting

FAERS reports

9,313

7,592 serious, 1,182 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 10, 2024.

Uses relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 5, 1998 Supplement 6 · Efficacy
  • Nov 15, 1995 Supplement 4 · Efficacy
  • Jun 19, 1995 Original approval · Type 8 - Partial Rx to OTC Switch
2 products under this application
  • TAGAMET HB · CIMETIDINE 200MG · TABLET, ORAL · Over-the-counter
  • TAGAMET HB · CIMETIDINE 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Cimetidine" as an intervention, any sponsor and status, largest first.

All 42 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease1,264
  • acute kidney injury716
  • nausea698
  • renal failure694
  • fatigue606
  • drug ineffective510
  • dyspnoea507
  • vomiting493
  • diarrhoea454
  • pain439
  • death403
  • dizziness388

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004351
2005479
2006351
2007186
2008275
2009279
2010321
2011368
2012647
2013288
2014222
2015349
2016348
2017350
2018685
20191,032
2020599
2021590
2022449
2023377
2024314
2025265
2026185

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,786 on PubMed

Sponsor: Medtech Products

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.